Is Tarlatamab-Imdelltra an immunotherapy drug?

Tarlatamab-Imdelltra is technically an immunotherapy drug. Its mechanism of action belongs to bispecific T cell connector (BiTE) technology. By simultaneously binding to tumor surface DLL3 molecules and T cell surface CD3 molecules, the patient's own T cells are "recruited" to the surrounding cancer cells, and the T cells are activated to release toxic particles to directly kill cancer cells. Unlike simple chemotherapy or targeted inhibitors, talatumumab relies on the power of the human immune system and is therefore classified as an immune drug.

Small cell lung cancer (ES-SCLC) is a highly aggressive tumor. Traditional treatment is chemotherapy, but the efficacy is limited. In recent years, immune checkpoint inhibitors such as PD-1/PD-L1 antibodies have shown certain activity in some patients, but the overall benefit has been limited. The emergence of talatumumab has opened up a new path for the application of immunotherapy in small cell lung cancer. It does not relieve immune suppression, but directly uses bispecific antibodies to accurately guide T cells to cancer cells, thus making up for the shortcomings of traditional immune drugs in SCLC.

In terms of clinical positioning, talatumumab is not a first-line drug that replaces chemotherapy, but is targeted at patients who still have disease progression after failure of platinum-based chemotherapy. As an immune drug, it has demonstrated a high objective response rate and durable response, which is particularly important for the ES-SCLC population who lack treatment options. Therefore, it can be clearly said that talatumumab is an immunological drug, which represents a new direction of immunotherapy in small cell lung cancer and also highlights the potential of bispecific antibodies as an emerging technology platform. As more research is conducted in the future, talatumumab may be expanded to other tumor types with high DLL3 expression.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html